{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:27:35Z","timestamp":1780514855063,"version":"3.54.1"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of cancer, enhancing response rates and survival outcomes. However, immune-related adverse events (irAEs), which can affect any organ or system, can limit their use. We report a rare case of hypophysitis in a triple-negative breast cancer patient receiving nivolumab, an anti-PD-1 monoclonal antibody. After six infusions of nivolumab, the patient developed hypocortisolism and hypothyroidism symptoms, such as mood swings, fatigue, unintentional weight loss, and vomiting. The diagnosis was confirmed by laboratory testing. The patient was successfully managed with hormone replacement therapy. Endocrinopathies can be life-threatening, necessitating treating doctors recognise their clinical symptoms, diagnose them, and manage them to ensure effective treatment and enhance the outcomes of immune checkpoint inhibitor-induced endocrine adverse effects.<\/jats:p>","DOI":"10.1093\/omcr\/omag060","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:39:10Z","timestamp":1774355950000},"source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab-associated hypopituitarism in a 61-year-old woman with metastatic triple-negative breast"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-7202","authenticated-orcid":false,"given":"Ketevan","family":"Lomidze","sequence":"first","affiliation":[{"name":"Department of Immunology, Department of Endocrinology, Tbilisi State Medical University , Vazha-Pshavela Str. #33, Tbilisi 0186 ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gordeladze","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tbilisi State Medical University , Vazha-Pshavela Str. #33, Tbilisi 0186 ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Kikodze","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tbilisi State Medical University , Vazha-Pshavela Str. #33, Tbilisi 0186 ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Charkviani","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tbilisi State Medical University , Vazha-Pshavela Str. #33, Tbilisi 0186 ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinatin","family":"Chikovani","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tbilisi State Medical University , Vazha-Pshavela Str. #33, Tbilisi 0186 ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"2026051007064703200_ref1","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"2026051007064703200_ref2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/cancers16071340","article-title":"Early serum markers for immune checkpoint inhibitor\u2013induced hypophysitis in melanoma patients","volume":"16","author":"Mitri","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026051007064703200_ref3","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"Castillero","year":"2019","journal-title":"Future Oncol"},{"key":"2026051007064703200_ref4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"2026051007064703200_ref5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J Biomed Sci"},{"key":"2026051007064703200_ref6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12902-021-00854-y","article-title":"Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report","volume":"21","author":"Antoniou","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"2026051007064703200_ref7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/1759-7714.13347","article-title":"Clinical diagnosis and treatment of immune checkpoint inhibitor\u2013related endocrine dysfunction","volume":"11","author":"Duan","year":"2020","journal-title":"Thorac Cancer"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/5\/omag060\/68262392\/omag060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/5\/omag060\/68262392\/omag060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:06:53Z","timestamp":1778411213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omag060\/8675264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omag060","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"omag060"}}